Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in Neurology Retrieve available abstracts of 343 articles: HTML format

Single Articles

November 2026
1. CORTESE R, Bianchi A, de Mauro A, Luchetti L, et al
   Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
   Neurology. 2026;107:e218673.
   PubMed     Abstract available
   
   
   
2. SHI JQ, Hong Y, Zhao HD, Jiang T, et al
   Reader Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
   Neurology. 2026;107:e214850.
   PubMed    
   
   
   
3. SIEGLER JE, Galetta SL
   Editors' Note: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
   Neurology. 2026;107:e218759.
   PubMed    
   
   
   
4. KRENN M, Wagner M, Cetin H
   Author Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
   Neurology. 2026;107:e214896.
   PubMed    
   
   
   
5. SEGAL Y, Aksamit AJ, McCarter SJ, Syc-Mazurek SB, et al
   "Railroad Track" Brain Fluorodeoxyglucose-PET Sign in Antiphospholipid Syndrome-Related Posterior Cortical Atrophy.
   Neurology. 2026;107:e218621.
   PubMed    
   
   
   
6. REYES-LEIVA D, Carbayo A, Vesperinas A, Caballero-Martinez F, et al
   Disease Control in Generalized Myasthenia Gravis: Consensus Definition, Evolution, and Patient Characterization.
   Neurology. 2026;107:e218557.
   PubMed     Abstract available
   
   
   
7. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
   Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
   Neurology. 2026;107:e218641.
   PubMed    
   
   
   October 2026
8. APAP MANGION S, Wade C, Coles D, Burton R, et al
   Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.
   Neurology. 2026;107:e218426.
   PubMed     Abstract available
   
   
   
9. GRAVESTEIJN AS, Nauta IM, Stob M, Wilmsen N, et al
   Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.
   Neurology. 2026;107:e218542.
   PubMed     Abstract available
   
   
   
10. OOI JCE, Leong SY, Pairan MS, Tan KY, et al
    Anti-Contactin-Associated Protein-Like-2 Antibody-Positive Morvan Syndrome With Myokymia in Thymoma-Associated Myasthenia Gravis.
    Neurology. 2026;107:e218562.
    PubMed    
    
    
    
11. BARTER KM, Thant A, Pitt M, Thotakura V, et al
    Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers.
    Neurology. 2026;107:e218575.
    PubMed     Abstract available
    
    
    
12. JAIN K, Storelli L, Valsasina P, Preziosa P, et al
    Disentangling Age-Related and Disease-Specific Effects on Upper Cervical Cord Area in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218517.
    PubMed     Abstract available
    
    
    
13. VRENKEN H
    Separating Disease Effects From Aging in Spinal Cord Atrophy in Multiple Sclerosis.
    Neurology. 2026;107:e218605.
    PubMed    
    
    
    
14. EL MAHDAOUI S, Pontieri L, Romme Christensen J, Alabdalridha H, et al
    Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
    Neurology. 2026;107:e218545.
    PubMed     Abstract available
    
    
    
15. LIAMPAS A, Artemiadis A, Tseriotis VS, Prados F, et al
    Prevalence of Slowly Expanding Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Neurology. 2026;107:e218474.
    PubMed     Abstract available
    
    
    
16. SUKHONPANICH N, Ngamsombat C, Buathong S, Thaneerat N, et al
    Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.
    Neurology. 2026;107:e218507.
    PubMed     Abstract available
    
    
    September 2026
17. FERNANDEZ V, Pappolla A, Carbonell-Mirabent P, Castillo M, et al
    Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.
    Neurology. 2026;107:e218451.
    PubMed     Abstract available
    
    
    
18. LAUERER M, Voon CC, McGinnis J, Sepp D, et al
    The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.
    Neurology. 2026;107:e218428.
    PubMed     Abstract available
    
    
    
19. SOLOMON AJ, Brownlee WJ, Viswanathan S, Fadda G, et al
    Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.
    Neurology. 2026;107:e218425.
    PubMed     Abstract available
    
    
    
20. GRANBERG T
    Paramagnetic Rim Lesions and Their Predictive Value of Future Progression in People With Multiple Sclerosis.
    Neurology. 2026;107:e218582.
    PubMed    
    
    
    
21. FURLAN R, Rossi E
    Longitudinal Neurofilament Light Chain Z-Score Dynamics: Bridging the Gap Between Research and Routine Monitoring in Multiple Sclerosis.
    Neurology. 2026;107:e218505.
    PubMed    
    
    
    
22. HACOHEN Y, Androdias G, Arrambide G, Bruijstens AL, et al
    De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.
    Neurology. 2026;107:e218482.
    PubMed     Abstract available
    
    
    
23. MOHAMED MI, Sameh R, Farghaly D, Ashraf B, et al
    Autoimmune Neurologic Disorders and the Risk of Alzheimer, Vascular, and Other Dementias: A Comprehensive Systematic Review and Meta-Analysis (P2-13.006).
    Neurology. 2026;107:e218536.
    PubMed    
    
    
    
24. KWON S, Kim BS, Han K, Heo NJ, et al
    Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.
    Neurology. 2026;107:e218377.
    PubMed     Abstract available
    
    
    
25. GIANNOCCARO MP, Serra L, Grondona AG, Ballestracci C, et al
    Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study.
    Neurology. 2026;107:e218301.
    PubMed     Abstract available
    
    
    
26. VINCENT A
    Cell-Based Assays: The New Gold Standard for Diagnosing Myasthenia Gravis?
    Neurology. 2026;107:e218495.
    PubMed    
    
    
    August 2026
27. BALSHI A, Alves C, Ullrich NJ, Benson LA, et al
    Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria.
    Neurology. 2026;107:e218240.
    PubMed     Abstract available
    
    
    
28. SCHOOF L, Heijnen R, Hogenboom L, Van Kempen ZLE, et al
    Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.
    Neurology. 2026;107:e218379.
    PubMed     Abstract available
    
    
    
29. PRESSLER H, Stascheit F, Aigner A, Doksani P, et al
    Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.
    Neurology. 2026;107:e218308.
    PubMed     Abstract available
    
    
    
30. MCLAREN NP, Rosati M, Zhong W, Hussain S, et al
    Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.
    Neurology. 2026;107:e218351.
    PubMed     Abstract available
    
    
    
31. KIMURA A, Takekoshi A, Maekawa Y, Tanaka K, et al
    Involvement of TNFRSF9 in the Pathogenesis of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2026;107:e218306.
    PubMed     Abstract available
    
    
    
32. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218310.
    PubMed     Abstract available
    
    
    July 2026
33. ENGELS D, Schindler P, Havla J, Fischer K, et al
    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.
    Neurology. 2026;107:e218199.
    PubMed     Abstract available
    
    
    
34. GUINEBRETIERE O, Yang F, Wei D, Calonge Q, et al
    Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).
    Neurology. 2026;107:e218072.
    PubMed     Abstract available
    
    
    
35. BOS L, Wink AM, Cole JH, Pontillo G, et al
    Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.
    Neurology. 2026;107:e218161.
    PubMed     Abstract available
    
    
    
36. ALLEN JA, Eftimov F, Querol L, Sommer C, et al
    Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Neurology. 2026;107:e218159.
    PubMed     Abstract available
    
    
    
37. SCHARF A, Cohen JA, Marrie RA, Miller AE, et al
    Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.
    Neurology. 2026;107:e218183.
    PubMed     Abstract available
    
    
    
38. TINTORE M, Rovira A
    Redefining Multiple Sclerosis: Toward a Biologically Driven Diagnosis.
    Neurology. 2026;107:e218210.
    PubMed    
    
    
    
39. MIRCHI A, Vossough A, Liu GT, Narula S, et al
    Pearls & Oy-sters: Radiologic Lag in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2026;107:e218254.
    PubMed     Abstract available
    
    
    June 2026
40. O'CONNOR L, Gabrysch K, Wikstrom AK, Rostedt Punga A, et al
    Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum: A Nationwide Cohort Study.
    Neurology. 2026;106:e218082.
    PubMed     Abstract available
    
    
    
41. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    PubMed     Abstract available
    
    
    
42. LAULETTA A, Rossini E, Beretta F, Damato V, et al
    Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.
    Neurology. 2026;106:e218081.
    PubMed     Abstract available
    
    
    
43. ROUX T, Lejeune FX, Casey R, Audoin B, et al
    French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.
    Neurology. 2026;106:e218073.
    PubMed     Abstract available
    
    
    
44. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    PubMed    
    
    
    
45. YAO Y, Li Y, Liu J, Ji Z, et al
    Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment.
    Neurology. 2026;106:e218120.
    PubMed     Abstract available
    
    
    
46. KIM W, Watt CL, Fung SG, Yoo S, et al
    Multiple Sclerosis and Outpatient Physician Care in the Last Years of Life: A Population-Based Study.
    Neurology. 2026;106:e218067.
    PubMed     Abstract available
    
    
    
47. LANZANTE M, Cerase A, de Mauro A, Forti A, et al
    Bridging the Gap: Balo Concentric Sclerosis-Like Leukoencephalopathy in Chronic Cocaine Use: A 1-Year Clinical and Imaging Follow-Up of 2 Cases.
    Neurology. 2026;106:e218068.
    PubMed     Abstract available
    
    
    
48. VAN STEENHOVEN RW, Bastiaansen AEM, Kerstens J, Crijnen YS, et al
    Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study.
    Neurology. 2026;106:e214933.
    PubMed     Abstract available
    
    
    May 2026
49. GAVOILLE A, Kerbrat A, Edan G, Le Page E, et al
    Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2026;106:e214943.
    PubMed     Abstract available
    
    
    
50. KVISTAD CE, Krakenes T, Holmoy T, Eidem LE, et al
    Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).
    Neurology. 2026;106:e214915.
    PubMed     Abstract available
    
    
    
51. PLUCHINO S, Mozafari S
    Early Human Intrathecal Mesenchymal Stem Cell Study in Progressive Multiple Sclerosis Faces Delivery Challenges.
    Neurology. 2026;106:e214955.
    PubMed    
    
    
    
52. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    PubMed    
    
    
    April 2026
53. TOURNIER A, Gavoille A, Pique J, Levraut M, et al
    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
    Neurology. 2026;106:e214806.
    PubMed     Abstract available
    
    
    
54. REMIJN-NELISSEN L, Bakker WR, van den Hout WB, van Gelder T, et al
    Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214865.
    PubMed     Abstract available
    
    
    
55. REMIJN-NELISSEN L, Bakker WR, van Gelder T, Moes DJAR, et al
    Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214715.
    PubMed     Abstract available
    
    
    
56. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    PubMed     Abstract available
    
    
    
57. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    PubMed    
    
    
    
58. DE JONG DJ, Schoonheim MM
    The Role of Wearable Devices to Identify Patients at High Risk of Disease Progression in Multiple Sclerosis.
    Neurology. 2026;106:e214742.
    PubMed    
    
    
    
59. FITZGERALD KC, Sanjayan M, Dewey BE, Guha Niyogi P, et al
    Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.
    Neurology. 2026;106:e214678.
    PubMed     Abstract available
    
    
    
60. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    PubMed     Abstract available
    
    
    
61. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    PubMed     Abstract available
    
    
    
62. SIRIRATNAM P, Jokubaitis VG, Van Der Walt A, Sanfilippo PG, et al
    Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2026;106:e214707.
    PubMed     Abstract available
    
    
    
63. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    PubMed     Abstract available
    
    
    
64. LEODORI G, Maccarrone D, Mancuso M, De Bartolo MI, et al
    Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.
    Neurology. 2026;106:e214778.
    PubMed     Abstract available
    
    
    
65. PEDERSON AM, Buto P, Zimmerman SC, Velez M, et al
    Type 1 Diabetes and Incident Dementia: An Analysis in the All of Us Cohort.
    Neurology. 2026;106:e214805.
    PubMed     Abstract available
    
    
    
66. DESCHAMPS R, Papeix C, Demortiere S, Lardeux P, et al
    Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.
    Neurology. 2026;106:e214753.
    PubMed     Abstract available
    
    
    
67. ALFREDSSON L, Johansson E, Olsson T, Stridh P, et al
    Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.
    Neurology. 2026;106:e214762.
    PubMed     Abstract available
    
    
    March 2026
68. BROWNLEE WJ, Maccarrone D, Nistri R, Yam C, et al
    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.
    Neurology. 2026;106:e214688.
    PubMed     Abstract available
    
    
    
69. ZHANG H, Janszky I, Arkema EV, Wang H, et al
    Autoimmune Diseases and Incident Spontaneous Subarachnoid Hemorrhage: A Swedish Population-Based Cohort Study.
    Neurology. 2026;106:e214679.
    PubMed     Abstract available
    
    
    
70. MILLER AE
    The 2024 McDonald Criteria for Diagnosis of Multiple Sclerosis: The Rubber Meets the Road.
    Neurology. 2026;106:e214688.
    PubMed    
    
    
    
71. CHANDRA A, Acharya S, Chandra A
    Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal: Overcoming Barriers Through Local Adaptations.
    Neurology. 2026;106:e214743.
    PubMed     Abstract available
    
    
    
72. PARAMASIVAN NK, Basal E, LaFrance-Corey RG, Arlt FA, et al
    Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies.
    Neurology. 2026;106:e214403.
    PubMed     Abstract available
    
    
    
73. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2026;106:e214694.
    PubMed    
    
    
    February 2026
74. TEO KSH, Kwan MYK, Qu D, Lim LHP, et al
    Patient Perspective: Words That Matter: Reflections on a Patient's Experiences With Guillain-Barre Syndrome.
    Neurology. 2026;106:e214685.
    PubMed     Abstract available
    
    
    
75. LOCKHART A, Pisa M, Drakesmith H, DeLuca GC, et al
    Iron-Rim Lesions in the Optic Chiasm in Multiple Sclerosis: A Neuropathologic Case Series.
    Neurology. 2026;106:e214515.
    PubMed     Abstract available
    
    
    
76. CAGOL A, Granziera C
    Turning Our Gaze to the Anterior Visual Pathway: Iron Rim Lesions Come Into View in Multiple Sclerosis.
    Neurology. 2026;106:e214590.
    PubMed    
    
    
    
77. NISTRI R, Cacciaguerra L, Sacco S, Virupakshaiah A, et al
    Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.
    Neurology. 2026;106:e214410.
    PubMed     Abstract available
    
    
    January 2026
78. BOS L, Wink AM, Cole JH, Strijbis EMM, et al
    Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age.
    Neurology. 2026;106:e214527.
    PubMed     Abstract available
    
    
    
79. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    PubMed     Abstract available
    
    
    
80. BARTELS F, Tapuc A, Rentzsch K, Duong SL, et al
    Memory Deficits in Cancer Patients With Serum NMDA Receptor Autoantibodies.
    Neurology. 2026;106:e214490.
    PubMed     Abstract available
    
    
    
81. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    PubMed    
    
    
    
82. SPAIN RI, Paz Soldan MM, Freedman MS, Repovic P, et al
    Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
    Neurology. 2026;106:e214454.
    PubMed     Abstract available
    
    
    
83. BRIGGS FBS, Amezcua L
    Alpha Lipoic Acid in Multiple Sclerosis: It's All in the Details.
    Neurology. 2026;106:e214578.
    PubMed    
    
    
    December 2025
84. HUANG X, Yu ZH, Cui Y, Zhang H, et al
    Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis.
    Neurology. 2025;105:e214428.
    PubMed     Abstract available
    
    
    
85. DAMULINA A, Opriessnig P, Pirpamer L, Demjaha R, et al
    Association of CSF Kappa-Free Light Chains With Cortical and Periventricular Brain Damage in Multiple Sclerosis.
    Neurology. 2025;105:e214433.
    PubMed     Abstract available
    
    
    
86. TRENTADUE T, Martinez Sosa S, Itoh CY, Modi T, et al
    Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.
    Neurology. 2025;105:e214429.
    PubMed     Abstract available
    
    
    
87. DE MEO E, Addazio I, Portaccio E, Bonacchi R, et al
    Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.
    Neurology. 2025;105:e214408.
    PubMed     Abstract available
    
    
    November 2025
88. DIMAURO KA, Manohar N, Aboseif A, Shah C, et al
    Leucine Zipper 4 Autoantibody-Associated Myeloneuropathy With Multiple Cranial Neuropathies and Longitudinally Extensive Tractopathy.
    Neurology. 2025;105:e214384.
    PubMed    
    
    
    
89. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;105:e214158.
    PubMed    
    
    
    
90. VILASECA A, Dalmau JO, Benarroch E
    What Are the Proposed Mechanisms Contributing to the Manifestations of Anti-NMDAR Encephalitis?
    Neurology. 2025;105:e214232.
    PubMed     Abstract available
    
    
    
91. TASHIRO T, Ogata H, Fukami Y, Maimaitijiang G, et al
    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.
    Neurology. 2025;105:e214143.
    PubMed     Abstract available
    
    
    
92. KOZIK V, Dreiling M, Muller D, Tiedge O, et al
    Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
    Neurology. 2025;105:e214217.
    PubMed     Abstract available
    
    
    
93. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    PubMed     Abstract available
    
    
    
94. VOROBYEV A, Buciuc M, Perez Giraldo GS, Grewal P, et al
    Clinical Reasoning: A 56-Year-Old Woman With Right-Sided Weakness and Recurrent MRI Lesions.
    Neurology. 2025;105:e214293.
    PubMed     Abstract available
    
    
    
95. PIERRET C, Leray E
    Author Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210260.
    PubMed    
    
    
    
96. GANESH A, Galetta SL
    Editors' Note: Understanding Cancer Risk Among Patients With Multiple Sclerosis.
    Neurology. 2025;105:e214342.
    PubMed    
    
    
    
97. SEJVAR JJ
    Guillain-Barre Syndrome: Grasping the "Rarity" of Outbreaks.
    Neurology. 2025;105:e214268.
    PubMed    
    
    
    
98. SONG Y, Wang L, Xuan Z
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210222.
    PubMed    
    
    
    
99. FENG Q
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210223.
    PubMed    
    
    
    October 2025
100. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
     Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
     Neurology. 2025;105:e213977.
     PubMed     Abstract available
     
     
     
101. O'NEILL KA, Charvet L, Waltz M, George A, et al
     Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
     Neurology. 2025;105:e214142.
     PubMed     Abstract available
     
     
     
102. OLIVIERI E, Muller J, Toosy AT
     Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
     Neurology. 2025;105:e214206.
     PubMed    
     
     
     
103. PORTACCIO E, Amato MP
     Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
     Neurology. 2025;105:e214244.
     PubMed    
     
     
     
104. LINDROOS JLV, Bjork MH, Cohen JM, Danielsson KC, et al
     Obstetric and Neonatal Outcomes in Patients With Maternal Myasthenia Gravis: A Nationwide Cohort Study.
     Neurology. 2025;105:e214139.
     PubMed     Abstract available
     
     
     
105. SAHI N, Ciccarelli O, Houlden H, Chard DT, et al
     Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.
     Neurology. 2025;105:e214141.
     PubMed     Abstract available
     
     
     
106. KRENN M, Wagner M, Schuller H, Pugna I, et al
     Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
     Neurology. 2025;105:e214177.
     PubMed     Abstract available
     
     
     
107. SERRAO C, Rodrigues R, Guerreiro CL, Oliveira J, et al
     Pearls & Oy-sters: Adult-Onset Coats Plus: A Case of Leukoencephalopathy With Calcifications, a Tumefactive Brain Lesion, and a Presumed Autoimmune Disease.
     Neurology. 2025;105:e214124.
     PubMed     Abstract available
     
     
     
108. NAUTIYAL K, Roy Chowdhury S, Meena R, Reddy N, et al
     Child Neurology: Parainfectious Anti-NMDAR Encephalitis With Anti-MOG and Anti-AQP4 Seropositivity in an Infant.
     Neurology. 2025;105:e214125.
     PubMed     Abstract available
     
     
     
109. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
     Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis.
     Neurology. 2025;105:e214069.
     PubMed     Abstract available
     
     
     
110. OVED K, Denkberg G, Pinzur L, Chroni E, et al
     Subunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis: A Multiparametric Cross-Sectional Analysis.
     Neurology. 2025;105:e214150.
     PubMed     Abstract available
     
     
     September 2025
111. THAKOLWIBOON S, Redenbaugh V, Chen B, Hewitt S, et al
     Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
     Neurology. 2025;105:e213903.
     PubMed     Abstract available
     
     
     
112. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
     Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
     Neurology. 2025;105:e214075.
     PubMed     Abstract available
     
     
     
113. RENNER B, Verter ED, Absinta M, Daboul L, et al
     Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
     Neurology. 2025;105:e213912.
     PubMed     Abstract available
     
     
     
114. CHARD DT
     Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
     Neurology. 2025;105:e214057.
     PubMed    
     
     
     
115. MAREFI A, Grasso EA, Canna SW, Behrens EM, et al
     Clinical Reasoning: A 9-Year-Old Girl With CNS Immune Dysregulation.
     Neurology. 2025;105:e213999.
     PubMed     Abstract available
     
     
     August 2025
116. HACOHEN Y, Ciccarelli O, Kunchok AC
     Diagnostic Criteria for Autoimmune Encephalitis in Children: Challenges and Need for Clinical Expertise.
     Neurology. 2025;105:e213946.
     PubMed    
     
     
     
117. SIEGLER JE, Galetta SL
     Editors' Note: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
     Neurology. 2025;105:e213926.
     PubMed    
     
     
     
118. MENON D, Bril V, Barnett-Tapia C
     Author Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
     Neurology. 2025;105:e210073.
     PubMed    
     
     
     
119. XU L, Zhou B, Xu Y
     Reader Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
     Neurology. 2025;105:e210041.
     PubMed    
     
     
     
120. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
     Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
     Neurology. 2025;105:e213907.
     PubMed     Abstract available
     
     
     
121. BSTEH G, Hegen H
     Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
     Neurology. 2025;105:e214073.
     PubMed    
     
     
     
122. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
     Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2025;105:e213967.
     PubMed     Abstract available
     
     
     
123. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
     Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
     Neurology. 2025;105:e213909.
     PubMed    
     
     
     
124. CORTESE M, Peng X, Edan G, Freedman MS, et al
     Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
     Neurology. 2025;105:e213905.
     PubMed     Abstract available
     
     
     
125. ROBIN C, Rollot F, Lefort M, Casey R, et al
     Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
     Neurology. 2025;105:e213744.
     PubMed     Abstract available
     
     
     
126. BOURDETTE D, Wooliscroft L
     Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
     Neurology. 2025;105:e213971.
     PubMed    
     
     
     
127. CABRAL A, Lopes da Mota C, Rodrigues Casanova S, Martins de Campos A, et al
     Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome.
     Neurology. 2025;105:e213848.
     PubMed     Abstract available
     
     
     July 2025
128. WU L, Jiang W, Du R, Liu Y, et al
     Clinical Reasoning: Acute and Progressive Cognitive Decline in a 38-Year-Old Man.
     Neurology. 2025;105:e213871.
     PubMed     Abstract available
     
     
     
129. PETERSSON M, Jons D, Feresiadou A, Ilinca A, et al
     Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.
     Neurology. 2025;105:e213771.
     PubMed     Abstract available
     
     
     
130. ZHOU J, Nilius S, Pilipczuk O, Scowcroft A, et al
     Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
     Neurology. 2025;105:e213736.
     PubMed     Abstract available
     
     
     
131. JIA A, Price TR, Rosner J, Broderick C, et al
     Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
     Neurology. 2025;105:e213663.
     PubMed     Abstract available
     
     
     June 2025
132. GOYNE C, Fair AE, Yilmaz D, Race J, et al
     Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
     Neurology. 2025;104:e213673.
     PubMed     Abstract available
     
     
     
133. JUL JARBAEK NIELSEN J, Levison L, Andersen H
     Mortality in Myasthenia Gravis in Denmark From 1985 to 2020: A Population-Based Cohort Study.
     Neurology. 2025;104:e213745.
     PubMed     Abstract available
     
     
     
134. YEH EA
     Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
     Neurology. 2025;104:e213840.
     PubMed    
     
     
     
135. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
     Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
     Neurology. 2025;104:e213650.
     PubMed     Abstract available
     
     
     May 2025
136. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
     Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
     Neurology. 2025;104:e213618.
     PubMed     Abstract available
     
     
     
137. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
     Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
     Neurology. 2025;104:e213607.
     PubMed     Abstract available
     
     
     
138. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
     Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
     Neurology. 2025;104:e213558.
     PubMed     Abstract available
     
     
     
139. FOX RJ, Rudick RA
     A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
     Neurology. 2025;104:e213672.
     PubMed    
     
     
     
140. DINOTO A, Cacciaguerra L, Vorasoot N, Redenbaugh V, et al
     Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
     Neurology. 2025;104:e213557.
     PubMed     Abstract available
     
     
     
141. VU AP, Kapadia RK, Roberts JI
     Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.
     Neurology. 2025;104:e213662.
     PubMed     Abstract available
     
     
     
142. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
     Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
     Neurology. 2025;104:e213587.
     PubMed     Abstract available
     
     
     
143. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
     Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
     Neurology. 2025;104:e213585.
     PubMed    
     
     
     
144. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
     Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
     Neurology. 2025;104:e213574.
     PubMed     Abstract available
     
     
     
145. ZARA P, Chessa P, Deiana GA, Morette AM, et al
     Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
     Neurology. 2025;104:e213498.
     PubMed     Abstract available
     
     
     
146. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
     Updated Multiple Sclerosis Incidence in France, 2011-2021.
     Neurology. 2025;104:e213586.
     PubMed     Abstract available
     
     
     April 2025
147. ZELIKOVICH AS, Zamorska B, Michaelson NM
     Patient Perspectives: Patient as Teacher: The Impact of Listening to a Patient With Stiff-Person Syndrome on Her Disease Course.
     Neurology. 2025;104:e213433.
     PubMed     Abstract available
     
     
     
148. NAKAJIMA A, Hokari M, Yanagimura F, Saji E, et al
     Long-Term Clinical Landscapes of Spinal Hypertrophic Pachymeningitis With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
     Neurology. 2025;104:e213420.
     PubMed     Abstract available
     
     
     
149. AL-SALAHAT A, Abdul Jabbar AB, Sharma R, Chen YT, et al
     Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022.
     Neurology. 2025;104:e213505.
     PubMed     Abstract available
     
     
     
150. ABBOUD H, Clardy SL, Dubey D, Wickel J, et al
     The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities.
     Neurology. 2025;104:e213487.
     PubMed     Abstract available
     
     
     
151. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
     Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
     Neurology. 2025;104:e210274.
     PubMed     Abstract available
     
     
     
152. GANESH A, Galetta SL
     Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
     Neurology. 2025;104:e213407.
     PubMed    
     
     
     
153. VIDAL-JORDANA A, Ontaneda D
     To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
     Neurology. 2025;104:e213416.
     PubMed    
     
     
     
154. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
     Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
     Neurology. 2025;104:e210259.
     PubMed     Abstract available
     
     
     
155. MAVRIDIS A, Viktorisson A, Eliasson B, von Euler M, et al
     Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden.
     Neurology. 2025;104:e213480.
     PubMed     Abstract available
     
     
     
156. MCAREE M, Frontera JA
     Clinical Reasoning: A 56-Year-Old Woman With New-Onset Hoarseness and Dysphagia.
     Neurology. 2025;104:e213363.
     PubMed     Abstract available
     
     
     March 2025
157. GOH WGW, Ng IKS, Tan MKX, Fong CYK, et al
     Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.
     Neurology. 2025;104:e213434.
     PubMed     Abstract available
     
     
     
158. MAILLART E, Dubessy AL, Shor N, Piljan M, et al
     Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2025;104:e213399.
     PubMed     Abstract available
     
     
     
159. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
     The Burden of Multiple Sclerosis in Mexico.
     Neurology. 2025;104:e213343.
     PubMed     Abstract available
     
     
     February 2025
160. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
     Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
     Neurology. 2025;104:e213349.
     PubMed     Abstract available
     
     
     
161. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
     Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
     Neurology. 2025;104:e210170.
     PubMed     Abstract available
     
     
     
162. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
     Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
     Neurology. 2025;104:e213330.
     PubMed     Abstract available
     
     
     
163. ROSS LA
     Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
     Neurology. 2025;104:e213366.
     PubMed    
     
     
     
164. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
     Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
     Neurology. 2025;104:e210142.
     PubMed     Abstract available
     
     
     
165. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
     Age-Related Disability Outcomes After a First Demyelinating Event.
     Neurology. 2025;104:e210305.
     PubMed     Abstract available
     
     
     
166. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
     Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
     Neurology. 2025;104:e210213.
     PubMed     Abstract available
     
     
     
167. ROCCA MA, Preziosa P, Filippi M
     Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
     Neurology. 2025;104:e213396.
     PubMed    
     
     
     
168. BRENTON JN
     Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
     Neurology. 2025;104:e213321.
     PubMed    
     
     
     
169. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
     Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
     Neurology. 2025;104:e210251.
     PubMed     Abstract available
     
     
     
170. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
     Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
     Neurology. 2025;104:e210281.
     PubMed     Abstract available
     
     
     
171. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
     Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
     Neurology. 2025;104:e213332.
     PubMed     Abstract available
     
     
     
172. 
     Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
     Neurology. 2025;104:e210299.
     PubMed    
     
     
     
173. 
     Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
     Neurology. 2025;104:e210298.
     PubMed    
     
     
     January 2025
174. TSAI CC, Chen J, Pikula A, Johnson EL, et al
     Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
     Neurology. 2025;104:e210289.
     PubMed     Abstract available
     
     
     
175. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
     Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
     Neurology. 2025;104:e210228.
     PubMed     Abstract available
     
     
     
176. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
     Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
     Neurology. 2025;104:e210149.
     PubMed     Abstract available
     
     
     
177. CARVALHO IV, Gomes F, Almendra L, Geraldo A, et al
     Reversible Unilateral Tongue Border Atrophy Associated With Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.
     Neurology. 2025;104:e210288.
     PubMed    
     
     
     
178. CAGOL A, Montobbio N
     Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
     Neurology. 2025;104:e210272.
     PubMed    
     
     
     
179. CRUCIANI A, Toosy AT
     Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
     Neurology. 2025;104:e210296.
     PubMed    
     
     
     
180. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
     Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2025;104:e210153.
     PubMed     Abstract available
     
     
     
181. WONG SH, Abuzaitoun R, Cornblath WT, Eggenberger ER, et al
     Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
     Neurology. 2025;104:e210150.
     PubMed     Abstract available
     
     
     
182. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
     Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
     Neurology. 2025;104:e210136.
     PubMed     Abstract available
     
     
     
183. CHEN B, Francis A, Cooper SA, Dobson R, et al
     Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2025;104:e210137.
     PubMed     Abstract available
     
     
     
184. JUL JARBAEK NIELSEN J, Levison L, Andersen H
     Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
     Neurology. 2025;104:e210139.
     PubMed     Abstract available
     
     
     December 2024
185. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
     Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
     Neurology. 2024;103:e210080.
     PubMed     Abstract available
     
     
     
186. BRENNER J, Ruhe CJ, Kulderij I, Bastiaansen AEM, et al
     Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.
     Neurology. 2024;103:e210109.
     PubMed     Abstract available
     
     
     
187. SIRIRATNAM P, Huda S, Van Der Walt A, Sanfilippo PG, et al
     Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
     Neurology. 2024;103:e209940.
     PubMed     Abstract available
     
     
     
188. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
     Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
     Neurology. 2024;103:e210140.
     PubMed     Abstract available
     
     
     
189. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
     Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
     Neurology. 2024;103:e210049.
     PubMed     Abstract available
     
     
     
190. CRANE PD, Sillau S, Dreher R, Fix R, et al
     Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System.
     Neurology. 2024;103:e210078.
     PubMed     Abstract available
     
     
     
191. KLEIN CJ, Triplett JD, Murray DL, Gorsh AP, et al
     Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
     Neurology. 2024;103:e210000.
     PubMed     Abstract available
     
     
     
192. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
     Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
     Neurology. 2024;103:e210003.
     PubMed     Abstract available
     
     
     
193. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
     Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
     Neurology. 2024;103:e209991.
     PubMed     Abstract available
     
     
     November 2024
194. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
     Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
     Neurology. 2024;103:e210004.
     PubMed     Abstract available
     
     
     
195. WATANABE M, Isobe N, Niino M, Nakashima I, et al
     Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
     Neurology. 2024;103:e209992.
     PubMed     Abstract available
     
     
     
196. SANTILLI AR, Ni O, Milone M, Selcen D, et al
     Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
     Neurology. 2024;103:e210001.
     PubMed     Abstract available
     
     
     
197. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
     Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
     Neurology. 2024;103:e210029.
     PubMed     Abstract available
     
     
     
198. SHARMA R, Bellacicco NJ, Husar WG, Park JH, et al
     Pearls & Oy-sters: Breaking Bad CIDP: Recognition of Anti-NF155 Autoimmune Nodopathy in Refractory CIDP.
     Neurology. 2024;103:e209848.
     PubMed    
     
     
     
199. MICHAELSON NM, Klawiter EC, Singhal T
     Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
     Neurology. 2024;103:e210047.
     PubMed    
     
     
     
200. PONTILLO G, Prados F, Colman J, Kanber B, et al
     Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
     Neurology. 2024;103:e209976.
     PubMed     Abstract available
     
     
     
201. BRUCKMAN D, Lee I, Schold JD, Claytor BR, et al
     Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019.
     Neurology. 2024;103:e210005.
     PubMed     Abstract available
     
     
     
202. 
     Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
     Neurology. 2024;103:e209968.
     PubMed    
     
     
     
203. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
     Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
     Neurology. 2024;103:e209952.
     PubMed     Abstract available
     
     
     
204. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
     Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
     Neurology. 2024;103:e209885.
     PubMed     Abstract available
     
     
     
205. GUPTA J, Choudhary R, Gupta A, Sharma P, et al
     Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation.
     Neurology. 2024;103:e209954.
     PubMed     Abstract available
     
     
     
206. SIEGLER JE, Galetta SL
     Editors' Note: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
     Neurology. 2024;103:e209934.
     PubMed    
     
     
     
207. MOEHLMAN M
     Author Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
     Neurology. 2024;103:e209565.
     PubMed    
     
     
     
208. YANG Y, Li J, Tang Y
     Reader Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
     Neurology. 2024;103:e209545.
     PubMed    
     
     
     
209. MARIGNIER R, Kunchok A
     Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.
     Neurology. 2024;103:e209970.
     PubMed    
     
     
     
210. RINGELSTEIN M, Asseyer S, Lindenblatt G, Fischer K, et al
     Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
     Neurology. 2024;103:e209888.
     PubMed     Abstract available
     
     
     October 2024
211. SILVERMAN A, Sasaki M, Espindola Lima JE, Cheronis C, et al
     Child Neurology: Remarkable Recovery From Severe Acute Necrotizing Encephalopathy.
     Neurology. 2024;103:e209877.
     PubMed     Abstract available
     
     
     
212. XU TT, Kaplan TM, Chen JJ
     Teaching NeuroImages: Cilioretinal Artery Occlusion Secondary to Antiphospholipid Syndrome.
     Neurology. 2024;103:e209901.
     PubMed    
     
     
     
213. SIEGLER JE 3RD, Galetta S
     Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209893.
     PubMed    
     
     
     
214. GROBOIS L, You M, Etienne M
     Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209508.
     PubMed    
     
     
     
215. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
     Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209515.
     PubMed    
     
     
     
216. HAY M, Rollot F, Casey R, Kerbrat A, et al
     Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
     Neurology. 2024;103:e209886.
     PubMed     Abstract available
     
     
     
217. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
     Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
     Neurology. 2024;103:e209874.
     PubMed    
     
     
     
218. ROBERTS JI, Ng D, Kapadia R
     Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis.
     Neurology. 2024;103:e209819.
     PubMed     Abstract available
     
     
     
219. 
     Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
     Neurology. 2024;103:e209905.
     PubMed    
     
     
     
220. 
     Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
     Neurology. 2024;103:e209461.
     PubMed    
     
     
     
221. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
     Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
     Neurology. 2024;103:e209663.
     PubMed     Abstract available
     
     
     
222. BLACKOWICZ M, James J, McNeil-Posey K, Schwartz T, et al
     Socioeconomic Factors Associated with >/=2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States.
     Neurology. 2024;103.
     PubMed     Abstract available
     
     
     
223. MANGIORIS G, Orozco E, Dubey D, Flanagan E, et al
     Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study.
     Neurology. 2024;103.
     PubMed     Abstract available
     
     
     
224. VENKATARAMAN I, Ott A, Miske R, Scharf M, et al
     Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.
     Neurology. 2024;103.
     PubMed     Abstract available
     
     
     September 2024
225. ROHM Z, Mobley B, Pawate S
     Teaching NeuroImage: Immunoglobulin G4-Related Hypophysitis.
     Neurology. 2024;103:e209809.
     PubMed    
     
     
     
226. ROVIRA A, Pareto D
     chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
     Neurology. 2024;103:e209735.
     PubMed    
     
     
     
227. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
     Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209604.
     PubMed     Abstract available
     
     
     
228. BOURDETTE D
     Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
     Neurology. 2024;103:e209835.
     PubMed    
     
     
     
229. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
     Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
     Neurology. 2024;103:e209752.
     PubMed     Abstract available
     
     
     
230. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
     Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209739.
     PubMed    
     
     
     
231. ZARA P, Solla P, Damato V, Sechi E, et al
     Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
     Neurology. 2024;103:e209756.
     PubMed    
     
     
     
232. SHIMIZU A, Noguchi-Shinohara M, Komatsu J, Ono K, et al
     Multifocal Intracranial Rosai-Dorfman Disease Mimicking Immunoglobulin G4-Related Pachymeningitis.
     Neurology. 2024;103:e209741.
     PubMed    
     
     
     
233. ABBOUD H, Farez MF
     The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
     Neurology. 2024;103:e209761.
     PubMed    
     
     
     
234. MOISSET X, Leray E, Chenaf C, Taithe F, et al
     Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
     Neurology. 2024;103:e209662.
     PubMed     Abstract available
     
     
     August 2024
235. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
     Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
     Neurology. 2024;103:e209706.
     PubMed     Abstract available
     
     
     
236. PASCUAL-GONI E, Caballero-Avila M, Querol L
     Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
     Neurology. 2024;103:e209725.
     PubMed     Abstract available
     
     
     
237. MENON D, Alharbi M, Katzberg HD, Bril V, et al
     Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
     Neurology. 2024;103:e209722.
     PubMed     Abstract available
     
     
     
238. TAGA A, Wali A, Eberhart CG, Green KE, et al
     Teaching NeuroImage: Giant Cell Arteritis With Optic Perineuritis.
     Neurology. 2024;103:e209707.
     PubMed    
     
     
     
239. WANG W
     Reader Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209441.
     PubMed    
     
     
     
240. WU J, Guo K, Liu J
     Author Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209463.
     PubMed    
     
     
     
241. LEWIS A, Galetta SL
     Editors' Note: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209736.
     PubMed    
     
     
     
242. 
     Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
     Neurology. 2024;103:e209640.
     PubMed    
     
     
     
243. 
     Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
     Neurology. 2024;103:e209639.
     PubMed    
     
     
     
244. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
     Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
     Neurology. 2024;103:e209598.
     PubMed     Abstract available
     
     
     
245. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
     Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
     Neurology. 2024;103:e209677.
     PubMed     Abstract available
     
     
     
246. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
     Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
     Neurology. 2024;103:e209610.
     PubMed     Abstract available
     
     
     July 2024
247. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
     Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
     Neurology. 2024;103:e209574.
     PubMed     Abstract available
     
     
     
248. GRANGEON L, Boulouis G, Capron J, Bala F, et al
     Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
     Neurology. 2024;103:e209548.
     PubMed     Abstract available
     
     
     
249. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
     Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
     Neurology. 2024;103:e209541.
     PubMed     Abstract available
     
     
     
250. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
     Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
     Neurology. 2024;103:e209444.
     PubMed     Abstract available
     
     
     
251. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
     Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
     Neurology. 2024;103:e209543.
     PubMed     Abstract available
     
     
     June 2024
252. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
     Does Surgical Removal of the Thymus Have Deleterious Consequences?
     Neurology. 2024;102:e209482.
     PubMed     Abstract available
     
     
     
253. PALLADINO R, Monasta L
     Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
     Neurology. 2024;102:e209521.
     PubMed    
     
     
     
254. ZHANG C, Liu W, Wang L, Wang F, et al
     Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
     Neurology. 2024;102:e209351.
     PubMed     Abstract available
     
     
     May 2024
255. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
     Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
     Neurology. 2024;102:e209303.
     PubMed     Abstract available
     
     
     
256. SILBERMANN E, Spain RI
     Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
     Neurology. 2024;102:e209456.
     PubMed    
     
     
     
257. FOX RJ, Cree BAC, de Seze J, Gold R, et al
     Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209357.
     PubMed     Abstract available
     
     
     
258. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
     Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
     Neurology. 2024;102:e209395.
     PubMed     Abstract available
     
     
     
259. LIAO J, Lu Y, Lu Y, Huang Y, et al
     Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
     Neurology. 2024;102:e209302.
     PubMed     Abstract available
     
     
     
260. MICHAELSON NM
     Right Brain: The Unraveling.
     Neurology. 2024;102:e209492.
     PubMed     Abstract available
     
     
     
261. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
     Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
     Neurology. 2024;102:e209350.
     PubMed     Abstract available
     
     
     
262. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
     Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
     Neurology. 2024;102:e209297.
     PubMed     Abstract available
     
     
     April 2024
263. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
     Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
     Neurology. 2024;102:e209282.
     PubMed     Abstract available
     
     
     
264. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
     Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
     Neurology. 2024;102:e209284.
     PubMed    
     
     
     
265. MOEHLMAN M, Kornbluh AB
     Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
     Neurology. 2024;102:e209259.
     PubMed    
     
     
     
266. 
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
     Neurology. 2024;102:e209214.
     PubMed    
     
     
     
267. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
     Pathologic Features of Anti-Ku Myositis.
     Neurology. 2024;102:e209268.
     PubMed     Abstract available
     
     
     
268. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
     MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
     Neurology. 2024;102:e209199.
     PubMed     Abstract available
     
     
     
269. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
     Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
     Neurology. 2024;102:e208114.
     PubMed     Abstract available
     
     
     
270. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
     Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
     Neurology. 2024;102:e209245.
     PubMed    
     
     
     
271. THAKOLWIBOON S, Dubey D
     Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
     Neurology. 2024;102:e209213.
     PubMed    
     
     
     
272. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
     Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
     Neurology. 2024;102:e208101.
     PubMed     Abstract available
     
     
     
273. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
     Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
     Neurology. 2024;102:e209257.
     PubMed    
     
     
     
274. AGYEI P, Chen M, Guo Y, Perez CA, et al
     Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
     Neurology. 2024;102:e209187.
     PubMed     Abstract available
     
     
     
275. KUHLMANN G, Cloud B
     Characterization of the Earliest Adopters of Subcutaneous FcRn Blockers for gMG (P4-14.013).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
276. YU Y, Kushlaf H
     Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
277. MASCANFRONI I, Manasson J, Pellerin A, Sanmarco L, et al
     Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
278. WATANABE F, Fedorko J, Imitola J
     Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
279. OHRN S, Patel R, Ali A, Bauerschmidt A, et al
     Autonomic Dysfunction in Autoimmune Encephalitis: A Review of the Literature (P6-14.004).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
280. ZAJNER C, Patil N, McInnis R, Van Uum S, et al
     Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (P7-10.005).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
281. ROBERTS K, Cohn B, Sista SR
     Acetylcholine Binding Receptor Positivity from Passive Antibody Transfer in a Case of Progressive Muscular Atrophy (P11-11.009).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
282. WEBER A, Rose J, DeWitt L
     NMOSD: Previously Seropositive Patient Presents with Seronegative Brainstem Attack (P11-14.017).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
283. LOBAINA M, Valaparla VL, Shanina E
     Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
284. HABIB AA, Kaminski HJ, Grosskreutz J, Mantegazza R, et al
     Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
285. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
     A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
286. ROSE M, Hsu S, Balan A, Anderson A, et al
     Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
287. JAFFRY K, Karpenos S, Lin J, Matos J, et al
     Climate Change Associated with Declining Clinical Outcomes in Myasthenia Gravis for US States with the Greatest Temperature Increase (P4-14.004).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
288. MAKAROVA A, Raju S, Ciotti J
     Parainfectious Hemorrhagic Longitudinally-extensive Transverse Myelitis Secondary to COVID-19 (P1-13.010).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
289. WOODSON S, Gettings E, Guo CY, Klineova S, et al
     Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
290. VARNET M, Kayani S, Wang C
     Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
291. MIKAMI T, Levy M
     Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     March 2024
292. YOUNG A, Johnston JL
     Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
     Neurology. 2024;102:e209260.
     PubMed     Abstract available
     
     
     
293. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
     Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
     Neurology. 2024;102:e209130.
     PubMed     Abstract available
     
     
     
294. MARRIE RA, Salter A
     Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
     Neurology. 2024;102:e208099.
     PubMed    
     
     
     
295. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
     Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e208032.
     PubMed     Abstract available
     
     
     
296. BOURDETTE D, Wooliscroft L
     The Challenges of Treating Late-Onset Multiple Sclerosis.
     Neurology. 2024;102:e209146.
     PubMed    
     
     
     
297. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
     Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
     Neurology. 2024;102:e208051.
     PubMed     Abstract available
     
     
     
298. 
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209252.
     PubMed    
     
     
     
299. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
     Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;102:e209135.
     PubMed     Abstract available
     
     
     
300. CHARD DT
     Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
     Neurology. 2024;102:e209246.
     PubMed    
     
     
     
301. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
     Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
     Neurology. 2024;102:e208058.
     PubMed     Abstract available
     
     
     
302. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
     Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
     Neurology. 2024;102:e209147.
     PubMed     Abstract available
     
     
     February 2024
303. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
     Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
     Neurology. 2024;102:e208019.
     PubMed     Abstract available
     
     
     
304. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
     Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
     Neurology. 2024;102:e208100.
     PubMed     Abstract available
     
     
     
305. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
     Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
     Neurology. 2024;102:e209153.
     PubMed    
     
     
     
306. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e207966.
     PubMed     Abstract available
     
     
     
307. WU J, Guo K, Liu J
     Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;102:e208064.
     PubMed     Abstract available
     
     
     
308. NG HS, Zhu F, Zhao Y, Yao S, et al
     Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
     Neurology. 2024;102:e208006.
     PubMed     Abstract available
     
     
     
309. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
     Patient With Rigidity and Fasciculations.
     Neurology. 2024;102:e208110.
     PubMed     Abstract available
     
     
     
310. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
     Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
     Neurology. 2024;102:e208059.
     PubMed     Abstract available
     
     
     January 2024
311. GIBSON S, Mcgraw C
     Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
     Neurology. 2024;102:e208027.
     PubMed     Abstract available
     
     
     
312. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
     Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
     Neurology. 2024;102:e207937.
     PubMed     Abstract available
     
     
     
313. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
     Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
     Neurology. 2024;102:e207916.
     PubMed     Abstract available
     
     
     
314. HABIB AA, Sacks N, Cool C, Durgapal S, et al
     Hospitalizations and Mortality From Myasthenia Gravis.
     Neurology. 2024;102:e207863.
     PubMed     Abstract available
     
     
     
315. LANGER-GOULD A, Sotirchos ES, Bourdette D
     Rituximab for Multiple Sclerosis.
     Neurology. 2024;102:e208063.
     PubMed     Abstract available
     
     
     
316. GALETTA S, Brownlee W
     Assignment Completed.
     Neurology. 2024;102:e207913.
     PubMed     Abstract available
     
     
     
317. TUR C, Rocca MA
     Progression Independent of Relapse Activity in Multiple Sclerosis.
     Neurology. 2024;102:e207936.
     PubMed     Abstract available
     
     
     
318. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
     Neurology. 2024;102:e200805.
     PubMed     Abstract available
     
     
     
319. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
     Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
     Neurology. 2024;102:e207768.
     PubMed     Abstract available
     
     
     
320. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
     Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2024;102:e207965.
     PubMed     Abstract available
     
     
     
321. ALKABIE S, Gray MT, Lau JC, Barra L, et al
     Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
     Neurology. 2024;102:e208018.
     PubMed     Abstract available
     
     
     December 2023
322. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
     Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
     Neurology. 2023;101:e2483-e2496.
     PubMed     Abstract available
     
     
     
323. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
     Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
     Neurology. 2023;101:e2585-e2588.
     PubMed     Abstract available
     
     
     
324. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
     Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
     Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
     PubMed     Abstract available
     
     
     November 2023
325. LI X, Stitt D, Lanzino G, Giannini C, et al
     Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
     Neurology. 2023;101:979-980.
     PubMed    
     
     
     October 2023
326. SRIVASTAVA I, Van Haren K
     Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
     Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
     PubMed    
     
     
     
327. BOURDETTE D, Silbermann E
     What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
     Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
     PubMed    
     
     
     
328. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
     Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
     Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
     PubMed     Abstract available
     
     
     
329. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
     Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
     Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
     PubMed     Abstract available
     
     
     
330. GUASP M, Dalmau J
     Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
     Neurology. 2023;101:656-660.
     PubMed     Abstract available
     
     
     
331. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
     Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
     PubMed     Abstract available
     
     
     
332. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
     Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
     Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
     PubMed     Abstract available
     
     
     September 2023
333. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
     Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
     Neurology. 2023;101:e1280-e1292.
     PubMed     Abstract available
     
     
     
334. PALLADINO R, Strijbis EM
     How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
     PubMed    
     
     
     
335. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
     Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
     PubMed     Abstract available
     
     
     
336. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
     Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
     PubMed     Abstract available
     
     
     
337. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
     Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
     PubMed     Abstract available
     
     
     
338. BUYUKKURT A, Harroud A
     The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
     PubMed    
     
     
     July 2023
339. QUINN C, Moulton K, Farwell M, Le W, et al
     Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
     PubMed     Abstract available
     
     
     
340. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
     Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
     PubMed     Abstract available
     
     
     
341. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
     Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
     PubMed     Abstract available
     
     
     September 2022
342. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
     Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
     PubMed     Abstract available
     
     
     August 2022
343. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
     Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
     Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum